Xizang Weixinkang Pharmaceutical Co (SHSE:603676) Cyclically Adjusted FCF per Share: ¥0.29 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603676 Xizang Weixinkang Pharmaceutical Co Ltd SHSE:603676
79 GF Score
Price ¥9.31
GF Value ¥8.90
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Xizang Weixinkang Pharmaceutical Co Cyclically Adjusted FCF per Share?

Xizang Weixinkang Pharmaceutical Co SHSE:603676 -0.11% 79 Cyclically Adjusted FCF per Share is ¥0.29 as of Mar. 2026. GuruFocus rates SHSE:603676 with a GF Score™ of 79/100 and a GF Value™ of ¥8.90 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Xizang Weixinkang Pharmaceutical Co's adjusted free cash flow per share for the three months ended in Mar. 2026 was ¥0.169. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ¥0.29 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Xizang Weixinkang Pharmaceutical Co's average Cyclically Adjusted FCF Growth Rate was 3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-18), Xizang Weixinkang Pharmaceutical Co's current stock price is ¥9.31. Xizang Weixinkang Pharmaceutical Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was ¥0.29. Xizang Weixinkang Pharmaceutical Co's Cyclically Adjusted Price-to-FCF of today is 32.10.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Xizang Weixinkang Pharmaceutical Co was 46.86. The lowest was 28.34. And the median was 40.06.


Xizang Weixinkang Pharmaceutical Co  (SHSE:603676) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Xizang Weixinkang Pharmaceutical Co's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=9.31/0.29
=32.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Xizang Weixinkang Pharmaceutical Co was 46.86. The lowest was 28.34. And the median was 40.06.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Xizang Weixinkang Pharmaceutical Co Cyclically Adjusted FCF per Share Related Terms


Xizang Weixinkang Pharmaceutical Co Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Xizang Weixinkang Pharmaceutical Co's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xizang Weixinkang Pharmaceutical Co Cyclically Adjusted FCF per Share Chart

Xizang Weixinkang Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.27

Xizang Weixinkang Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.28 0.27 0.27 0.29

SHSE:603676 vs ZTS: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Xizang Weixinkang Pharmaceutical Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xizang Weixinkang Pharmaceutical Co Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Xizang Weixinkang Pharmaceutical Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Xizang Weixinkang Pharmaceutical Co's Cyclically Adjusted Price-to-FCF falls into.


SHSE:603676
79GF Score
Xizang Weixinkang Pharmaceutical Co Ltd SHSE:603676
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xizang Weixinkang Pharmaceutical Co Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xizang Weixinkang Pharmaceutical Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.169/116.3033*116.3033
=0.169

Current CPI (Mar. 2026) = 116.3033.

Xizang Weixinkang Pharmaceutical Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.196 101.400 0.225
201609 0.017 102.400 0.019
201612 0.084 102.600 0.095
201703 -0.015 103.200 -0.017
201706 0.114 103.100 0.129
201709 -0.033 104.100 -0.037
201712 -0.087 104.500 -0.097
201803 -0.100 105.300 -0.110
201806 0.104 104.900 0.115
201809 0.040 106.600 0.044
201812 -0.072 106.500 -0.079
201903 0.115 107.700 0.124
201906 -0.194 107.700 -0.209
201909 -0.034 109.800 -0.036
201912 0.280 111.200 0.293
202003 -0.032 112.300 -0.033
202006 0.005 110.400 0.005
202009 0.092 111.700 0.096
202012 0.120 111.500 0.125
202103 -0.038 112.662 -0.039
202106 0.140 111.769 0.146
202109 0.043 112.215 0.045
202112 0.169 113.108 0.174
202203 0.013 114.335 0.013
202206 0.166 114.558 0.169
202209 0.128 115.339 0.129
202212 0.083 115.116 0.084
202303 0.086 115.116 0.087
202306 0.026 114.558 0.026
202309 0.154 115.339 0.155
202312 0.134 114.781 0.136
202403 0.253 115.227 0.255
202406 0.152 114.781 0.154
202409 0.189 115.785 0.190
202412 0.133 114.893 0.135
202503 0.086 115.116 0.087
202506 0.089 114.907 0.090
202509 -0.024 115.471 -0.024
202512 0.081 115.832 0.081
202603 0.169 116.303 0.169

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of ¥0.29 mean?
Xizang Weixinkang Pharmaceutical Co (SHSE:603676) has a Cyclically Adjusted FCF per Share of ¥0.29 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Xizang Weixinkang Pharmaceutical Co and its competitors.
Is Xizang Weixinkang Pharmaceutical Co's Cyclically Adjusted FCF per Share too high?
Xizang Weixinkang Pharmaceutical Co's current Cyclically Adjusted FCF per Share is ¥0.29. Overall, Xizang Weixinkang Pharmaceutical Co has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Xizang Weixinkang Pharmaceutical Co's Cyclically Adjusted FCF per Share compare to ZTS?
Xizang Weixinkang Pharmaceutical Co's Cyclically Adjusted FCF per Share of ¥0.29 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Xizang Weixinkang Pharmaceutical Co and its competitors. Xizang Weixinkang Pharmaceutical Co's current Cyclically Adjusted FCF per Share is ¥0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xizang Weixinkang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co (SHSE:603676) is currently considered Fairly Valued. The stock's GF Value™ is ¥8.90, compared to a current price of ¥9.31 — trading 4.6% above its estimated fair value. The current Cyclically Adjusted FCF per Share is ¥0.29. Xizang Weixinkang Pharmaceutical Co's overall GF Score™ is 79/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Xizang Weixinkang Pharmaceutical Co (SHSE:603676), the current Cyclically Adjusted FCF per Share is ¥0.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xizang Weixinkang Pharmaceutical Co (SHSE:603676) Overvalued in 2026?

Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥9.31 is trading 4.6% above its estimated GF Value™ of ¥8.90. GuruFocus considers Xizang Weixinkang Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:603676:

  • Cyclically Adjusted FCF per Share: ¥0.29
  • GF Value™: ¥8.90 vs. price of ¥9.31 (4.6% above fair value)
  • GF Score™: 79/100 with 2 warning signs

No single metric tells the full story. See the SHSE:603676 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xizang Weixinkang Pharmaceutical Co Business Description

Address Yuanqu South Road, 3rd Floor, Building 4, Industrial Center, No. 5, Zone B, Lhasa Economic and Technological, Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Xizang Weixinkang Pharmaceutical Co Ltd is engaged in research & development, production and sales of chemical pharmaceutical preparations and their raw materials. It also produces and sells liver protection drugs and antibiotic products.
79GF Score

Get the complete analysis for SHSE:603676

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥9.31
Price
¥8.90
GF Value